This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Related articles in BJP
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by WILSON, K. C. M.
Right arrow Articles by ABOU-SALEH, M. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by WILSON, K. C. M.
Right arrow Articles by ABOU-SALEH, M. T.
The British Journal of Psychiatry (2003) 182: 492-497
© 2003 The Royal College of Psychiatrists

Older community residents with depression: long-term treatment with sertraline

Randomised, double-blind, placebo-controlled study

K. C. M. WILSON, MBChB, MPhil, MD, FRCPsych, P. G. MOTTRAM, BSc,MSc,PhD, L. ASHWORTH, MBChB, MRCPsych and M. T. ABOU-SALEH, MBChB, MPhil, PhD, FRCPsych

University of Liverpool, UK

Correspondence: Professor K.C. M.Wilson, EMI Academic Unit, St Catherine's Hospital, Derby Road, Birkenhead CH42 0LQ,UK. Fax: 0151 653 3441; e-mail: kw500505{at}liverpool.ac.uk

Declaration of interest The study was sponsored by Pfizer Ltd.

Background Despite a growing use of selective serotonin reuptake inhibitors in older people, only one trial has examined their prophylactic efficacy in people aged 65 years and over.

Aims To examine the efficacy of sertraline in preventing the recurrence of depression in older people living in the community.

Method Participants were openly treated with sertraline and then randomised into a double-blind, placebo-controlled continuation/maintenance study of about 2 years duration. Drug dosage was maintained at levels that achieved remission.

Results No significant difference between the sertraline and placebo groups was found in the proportion of recurrences (–7.9%; 95% CI –28.06 to 12.23). Increased age and minor residual symptoms during the continuation phase were associated with recurrence.

Conclusions Sertraline attherapeutic dosage does not provide significant protection against recurrence.


Related articles in BJP:

Highlights of this issue
ELIZABETH WALSH
BJP 2003 182: 465-a23. [Full Text]  



This article has been cited by other articles:


Home page
 ANN INTERN MEDHome page
G. Gartlehner, B. N. Gaynes, R. A. Hansen, P. Thieda, A. DeVeaugh-Geiss, E. E. Krebs, C. G. Moore, L. Morgan, and K. N. Lohr
Comparative Benefits and Harms of Second-Generation Antidepressants: Background Paper for the American College of Physicians
Ann Intern Med, November 18, 2008; 149(10): 734 - 750.
[Abstract] [Full Text] [PDF]

Home page
 Psychiatr. Serv.Home page
R. Hansen, B. Gaynes, P. Thieda, G. Gartlehner, A. Deveaugh-Geiss, E. Krebs, and K. Lohr
Meta-analysis of Major Depressive Disorder Relapse and Recurrence With Second-Generation Antidepressants
Psychiatr Serv, October 1, 2008; 59(10): 1121 - 1130.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. M. Williams, R. E. Clouse, B. D. Nix, E. H. Rubin, G. S. Sayuk, J. B. McGill, A. J. Gelenberg, P. S. Ciechanowski, I. B. Hirsch, and P. J. Lustman
Efficacy of Sertraline in Prevention of Depression Recurrence in Older Versus Younger Adults With Diabetes
Diabetes Care, April 1, 2007; 30(4): 801 - 806.
[Abstract] [Full Text] [PDF]

Home page
 Evid. Based Ment. HealthHome page
K. I Shulman
Continuing paroxetine treatment reduces recurrence of major depression in the elderly.
Evid. Based Ment. Health, November 1, 2006; 9(4): 101 - 101.
[Full Text] [PDF]

Home page
 Evid. Based Nurs.Home page
C. E Wills
Maintenance treatment with paroxetine, but not psychotherapy, prevented recurrent major depression in older people
Evid. Based Nurs., October 1, 2006; 9(4): 119 - 119.
[Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
P. J. Lustman, R. E. Clouse, B. D. Nix, K. E. Freedland, E. H. Rubin, J. B. McGill, M. M. Williams, A. J. Gelenberg, P. S. Ciechanowski, and I. B. Hirsch
Sertraline for Prevention of Depression Recurrence in Diabetes Mellitus: A Randomized, Double-blind, Placebo-Controlled Trial.
Arch Gen Psychiatry, May 1, 2006; 63(5): 521 - 529.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
C. F. Reynolds III, M. A. Dew, B. G. Pollock, B. H. Mulsant, E. Frank, M. D. Miller, P. R. Houck, S. Mazumdar, M. A. Butters, J. A. Stack, et al.
Maintenance treatment of major depression in old age.
N. Engl. J. Med., March 16, 2006; 354(11): 1130 - 1138.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
F. E. Lotrich and B. G. Pollock
Aging and Clinical Pharmacology: Implications for Antidepressants
J. Clin. Pharmacol., October 1, 2005; 45(10): 1106 - 1122.
[Abstract] [Full Text] [PDF]

Home page
 Evid. Based Ment. HealthHome page
L. S Schneider
Venlafaxine offers no benefit over sertraline and is less well tolerated in depressed nursing home residents
Evid. Based Ment. Health, May 1, 2004; 7(2): 47 - 47.
[Full Text] [PDF]

Home page
 Adv. Psychiatr. Treat.Home page
R. Baldwin and R. Wild
Management of depression in later life
Adv. Psychiatr. Treat., March 1, 2004; 10(2): 131 - 139.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
S. Kumar and K. C. M. Wilson
Prophylaxis of depression in older people * Author's reply
The British Journal of Psychiatry, October 1, 2003; 183(4): 365 - 365.
[Full Text] [PDF]

eLetters:

Read all eLetters

Insignificant protection against recurrent depression with sertraline- how valid is the conclusion?
Sudhir Kumar
BJP Online, 5 Jun 2003 [Full text]
Insignificant protection against recurrent depression with sertraline-how valid is the conclusion.
Kenneth C Wilson
BJP Online, 11 Jun 2003 [Full text]